Definition and characterization of an inhibitor for interleukin-31

Emilie Venereau, Caroline Diveu, Linda Grimaud, Elisa Ravon, Josy Froger, Laurence Preisser, Yannic Danger, Mike Maillasson, Laure Garrigue-Antar, Yannick Jacques, Sylvie Chevalier, Hugues Gascan

Research output: Contribution to journalArticlepeer-review


Interleukin-31 (IL-31) is a recently described T cell-derived cytokine, mainly produced by T helper type 2 cells and related to the IL-6 cytokine family according to its structure and receptor. IL-31 is the ligand for a heterodimeric receptor composed of a gp130-like receptor (GPL) associated with the oncostatin M receptor (OSMR). A link between IL-31 and atopic dermatitis was shown by studying the phenotype of IL-31 transgenic mice and IL-31 gene haplotypes in patients suffering from dermatitis. In this study, we generated a potent IL-31 antagonist formed by external portions of OSMR and GPL fused with a linker. This fusion protein, OSMR-LGPL, consisting of 720 amino acids, counteracted the binding of IL-31 to its membrane receptor complex and the subsequent signaling events involving the STATs and MAPK path-ways. Neutralizing effects were found in IL-31-sensitive cell lines, including brain-derived cells and primary cultures of keratinocytes.

Original languageEnglish
Pages (from-to)14955-14963
Number of pages9
JournalJournal of Biological Chemistry
Issue number20
Publication statusPublished - May 14 2010

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology


Dive into the research topics of 'Definition and characterization of an inhibitor for interleukin-31'. Together they form a unique fingerprint.

Cite this